RXI Pharma (RXII) Reports Encouraging Prelim. Results from RXI-109-1301 Phase 2a
Tweet Send to a Friend
RXI Pharma (NASDAQ: RXII) announced completion of enrollment in its first Phase 2a study, RXI-109-1301. The preliminary results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE